glp 1 and energy GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes obesity | Saudi Pharmaceutical Journal GLP-1 and the Degenerating Brain:

Understanding how long your medication lasts in the refrigerator and following storage best practices ensures optimal potency and safety throughout your weight loss therapy

Liraglutide (NN2211) is a long-acting GLP-1 receptor agonist used to treat type 2 diabetes and obesity (Victoza, Saxenda)

Back in 1990, an endocrinologist named John Eng was

How she got into practice and how she got into the GLP-1 space

A retrospective analysis of 105,000+ patients revealed: 40% lower OSA risk with tirzepatide (Zepbound) or semaglutide (Wegovy) vs non-AOM users Lower OSA incidence: 3.12% vs 12.56% Comparable impact between tirzepatide and semaglutide, with tirzepatide showing a slight edge after 6 months This study highlights the potential for AOMs to address obesity and OSA, supporting broader healthcare value through comorbidity reduction

Slows digestion, so you feel fuller for longer